651 related articles for article (PubMed ID: 18451130)
1. Oncogene addiction.
Weinstein IB; Joe A
Cancer Res; 2008 May; 68(9):3077-80; discussion 3080. PubMed ID: 18451130
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
Weinstein IB; Joe AK
Nat Clin Pract Oncol; 2006 Aug; 3(8):448-57. PubMed ID: 16894390
[TBL] [Abstract][Full Text] [Related]
3. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
Felsher DW
Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
[TBL] [Abstract][Full Text] [Related]
4. Tumor dormancy and oncogene addiction.
Felsher DW
APMIS; 2008; 116(7-8):629-37. PubMed ID: 18834407
[TBL] [Abstract][Full Text] [Related]
5. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation.
Sharma SV; Fischbach MA; Haber DA; Settleman J
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4392s-4395s. PubMed ID: 16857816
[TBL] [Abstract][Full Text] [Related]
6. [Molecular cancer biology--from research to clinical practice].
Nielsen FC
Ugeskr Laeger; 2003 Feb; 165(9):897-900. PubMed ID: 12661511
[TBL] [Abstract][Full Text] [Related]
7. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
8. Oncogene addiction: setting the stage for molecularly targeted cancer therapy.
Sharma SV; Settleman J
Genes Dev; 2007 Dec; 21(24):3214-31. PubMed ID: 18079171
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of oncogene-induced cancer.
Felsher DW
Curr Opin Genet Dev; 2004 Feb; 14(1):37-42. PubMed ID: 15108803
[TBL] [Abstract][Full Text] [Related]
10. Cancer biology: signatures guide drug choice.
Downward J
Nature; 2006 Jan; 439(7074):274-5. PubMed ID: 16421553
[No Abstract] [Full Text] [Related]
11. Oncogene-induced senescence: the bright and dark side of the response.
Gorgoulis VG; Halazonetis TD
Curr Opin Cell Biol; 2010 Dec; 22(6):816-27. PubMed ID: 20807678
[TBL] [Abstract][Full Text] [Related]
12. Oncogene addiction: role of signal attenuation.
Hübner A; Jaeschke A; Davis RJ
Dev Cell; 2006 Dec; 11(6):752-4. PubMed ID: 17141149
[TBL] [Abstract][Full Text] [Related]
13. Oncogenes and cancer.
Croce CM
N Engl J Med; 2008 Jan; 358(5):502-11. PubMed ID: 18234754
[No Abstract] [Full Text] [Related]
14. Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy.
Yan R; Hallam A; Stockley PG; Boyes J
Biochem J; 2014 Jul; 461(1):1-13. PubMed ID: 24927119
[TBL] [Abstract][Full Text] [Related]
15. From oncogene to network addiction: the new frontier of cancer genomics and therapeutics.
Tonon G
Future Oncol; 2008 Aug; 4(4):569-77. PubMed ID: 18684067
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective.
Heng HH; Bremer SW; Stevens JB; Ye KJ; Liu G; Ye CJ
J Cell Physiol; 2009 Sep; 220(3):538-47. PubMed ID: 19441078
[TBL] [Abstract][Full Text] [Related]
17. Phosphoproteomics, oncogenic signaling and cancer research.
Chong PK; Lee H; Kong JW; Loh MC; Wong CH; Lim YP
Proteomics; 2008 Nov; 8(21):4370-82. PubMed ID: 18814326
[TBL] [Abstract][Full Text] [Related]
18. Cancer therapy: switching off oncogenes.
Pompetti F; Pilla D; Giancola R
Bioessays; 2003 Feb; 25(2):104-7. PubMed ID: 12539235
[TBL] [Abstract][Full Text] [Related]
19. Transient oncogenes.
Lenz G
Med Hypotheses; 2010 Dec; 75(6):660-2. PubMed ID: 20800367
[TBL] [Abstract][Full Text] [Related]
20. Molecular aspects of carcinogenesis in pancreatic cancer.
Koliopanos A; Avgerinos C; Paraskeva C; Touloumis Z; Kelgiorgi D; Dervenis C
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):345-56. PubMed ID: 18693168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
